Lipidomics in Understanding Pathophysiology and Pharmacologic Effects in Inflammatory Diseases: Considerations for Drug Development.

Ahluwalia, Kabir; Ebright, Brandon; Chow, Kingsley; Dave, Priyal; Mead, Andrew; Poblete, Roy; Louie, Stan G; Asante, Isaac

Ahluwalia, Kabir; Ebright, Brandon; Chow, Kingsley; Dave, Priyal; Mead, Andrew; Poblete, Roy; Louie, Stan G; Asante, Isaac.

Afiliação

Ahluwalia K; School of Pharmacy, University of Southern California, Los Angeles, CA 90089, USA.
Ebright B; School of Pharmacy, University of Southern California, Los Angeles, CA 90089, USA.
Chow K; School of Pharmacy, University of Southern California, Los Angeles, CA 90089, USA.
Dave P; School of Pharmacy, University of Southern California, Los Angeles, CA 90089, USA.
Mead A; School of Pharmacy, University of Southern California, Los Angeles, CA 90089, USA.
Poblete R; Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Louie SG; School of Pharmacy, University of Southern California, Los Angeles, CA 90089, USA.
Asante I; Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.

Metabolites ; 12(4)2022 Apr 07.

Article em En | MEDLINE | ID: mdl-35448520

Palavras-chave

autoimmune disease; cardiovascular disease; eicosanoids; inflammation; lipid mediators; lipidomics; mass spectrometry; neurodegeneration; respiratory disease; special pro-resolving lipid mediators

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Ano de publicação: 2022 Tipo de documento: Article